Cipla Ltd

The board of Cipla at its meeting held on 23 July 2026 has approved the following: Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026. Appointment of Dinesh Jain, Chief ' Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.

Cipla has granted 24,709 stock options and employee stock appreciation rights on 23 July 2026.

Revenue from operations increased 3.51% YoY to Rs 7,077.02 crore in the quarter ended 30th June 2026. Profit before tax (PBT) fell 38.87% YoY to Rs 1,081.93 crore in Q1 FY27. EBITDA stood at Rs 1,192 crore, down 32.96% compared with Rs 1,778 crore in Q1 FY26, while the EBITDA margin contracted to 16.7% from 25.6% a year earlier. On the business front, the India business remained the key growth driver, with revenue rising 12% year-on-year to Rs 3,452 crore. Revenue from One Africa- comprising South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access - also grew 12% to Rs 977 crore, while Emerging Markets and Europe recorded 16% growth to Rs 999 crore. However, revenue from North America declined 21% year-on-year to Rs 1,532 crore, while the API and other business segment fell 28% to Rs 160 crore during the quarter. During the quarter, research and development (R&D) expenditure increased 12.3% year-on-year to Rs 486 crore, accounting for 6.8% of sales, driven by higher product filings and ongoing development initiatives. Achin Gupta MD and Global CEO, Cipla, said, 'We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs 7,119 crore. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of $162 million during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.' Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.Powered by Capital Market - Live

Net profit of Cipla declined 39.19% to Rs 789.05 crore in the quarter ended June 2026 as against Rs 1297.62 crore during the previous quarter ended June 2025. Sales rose 3.51% to Rs 7077.02 crore in the quarter ended June 2026 as against Rs 6837.04 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales7077.026837.04 4 OPM %16.8526.01 - PBDT1386.172022.65 -31 PBT1081.931769.93 -39 NP789.051297.62 -39 Powered by Capital Market - Live

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.

Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1476.6, up 2.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.46% on the day, quoting at 23944.45. The Sensex is at 76716.34, down 0.5%. Cipla Ltd has risen around 6.21% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 4.4% in last one month and is currently quoting at 24969.5, up 1.25% on the day. The volume in the stock stood at 20.59 lakh shares today, compared to the daily average of 15.8 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1472.9, up 2.22% on the day. Cipla Ltd is down 1.95% in last one year as compared to a 6.16% drop in NIFTY and a 14.71% drop in the Nifty Pharma index.The PE of the stock is 33.8 based on TTM earnings ending March 26.Powered by Capital Market - Live

Cipla announced that ESG Risk Assessments & Insights Limited, a SEBI registered ESG Rating Provider (ESGRisks.ai), has revised the Company's ESG rating from 68 to 64. The revision is based on re-evaluation of publicly available information and certain new information considered during the assessment period.

Cipla will hold a meeting of the Board of Directors of the Company on 23 July 2026.

The target price indicates a potential upside of about 20.23% from the current market price. The brokerage expects a series of near-term developments to support the stock. These include the anticipated approval of gFlovent from Cipla's Goa facility and the planned launch of gVentolin, both of which could strengthen the company's position in the US market. The brokerage also highlighted the strong performance of Nintedanib in the US, where the product has captured nearly half of the market. It expects Cipla's US business to return to growth after a period of weakness. The brokerage said the company's India business remains resilient, supported by a recovery in its respiratory portfolio. It added that a re-inspection of Cipla's Indore manufacturing facility is expected shortly, and a favourable outcome along with USFDA clearance could act as an additional trigger for the stock. The brokerage further noted that easing geopolitical tensions have reduced concerns over raw material costs and margin pressures. According to the report, the earnings impact from the decline in gRevlimid-related sales has largely played out, suggesting that Cipla's profit cycle may have bottomed out. The stock is currently valued at around 25 times FY27 estimated earnings and 21 times FY28 estimated earnings. The brokerage said Cipla offers a compelling combination of domestic pharmaceutical exposure, improving US business prospects and attractive valuations. It noted that the company's India business is valued at 7.8 times FY26 sales, compared with 8.5 times for peer Mankind Pharma, making the risk-reward profile favourable. Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets. The drug major's consolidated net profit stood at Rs 554.64 crore in Q4 FY26, down 54.61% from Rs 1,221.84 crore in Q4 FY25. Revenue from operations declined 2.02% YoY to Rs 6,464.26 crore in Q4 FY26 from Rs 6,597.72 crore in the year-ago period. Powered by Capital Market - Live

Puri, who currently serves as managing director (MD) and chief executive officer (CEO) of Cipla Health, a wholly owned subsidiary of Cipla, will also be designated as a Senior Management Personnel of the company. The appointment is on a full-time employment basis, Cipla said in a regulatory filing. Puri has been leading Cipla Health since 2019 and has played a key role in expanding its consumer healthcare and wellness portfolio across categories such as smoking cessation, pain care, cough and cold, skincare, haircare and nutrition. Under his leadership, the business evolved from a startup venture into one of India's leading wellness-focused consumer goods companies. He brings more than 23 years of leadership experience across the FMCG and healthcare sectors. Before joining Cipla Health, Puri held senior leadership positions at Hindustan Unilever Ltd, Jubilant FoodWorks Ltd and ITC Ltd. During his tenure at Hindustan Unilever, he managed multiple businesses, including the Pureit water purifier portfolio, homecare division and modern trade operations, besides overseeing brands such as Surf Excel. Puri holds a Bachelor of Technology degree from IIT (BHU) Varanasi and an MBA from the Indian Institute of Management (IIM), Lucknow. Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets. The drug major's consolidated net profit stood at Rs 554.64 crore in Q4 FY26, down 54.61% from Rs 1,221.84 crore in Q4 FY25. Revenue from operations declined 2.02% YoY to Rs 6,464.26 crore in Q4 FY26 from Rs 6,597.72 crore in the year-ago period. Shares of Cipla shed 0.63% to end at Rs 1,372.75 on the BSE. Powered by Capital Market - Live